Biotech Companies Patents Invalid After Crispr Ruling

    On Monday, the U.S. Patent and Trademark Office said that the first person to invent the CRISPR-Cas9 technology for their use in the animal cell was the Broad Institute, siding against the two Nobel Laureates. The Monday ruling on the long-running dispute jeopardizes licensing agreements of a few biotech companies

    More on the story

    As per Bloomberg News, the ruling on Monday determined that the Nobel winners Emmanuelle Charpentier from the University of Vienna and Jennifer Doudna from the University of California at Berkeley had failed to provide evidence that the two were the first to use in animal cells, their gene-editing technology. 

    The patent battle went on for years. The University of Vienna and the University of California, Berkley had contended that their scientists were the first to find a solution to guide Crispr-Cas9 to specific locations on the genome. The broad Institute maintained that their scientists first proved that their technology worked in animals, humans, and plants. 

    Several biotechnology companies, including Crispr Therapeutics AG and Intellia Therapeutics Inc., had licensed the Crispr-Cas9 technology from the University of Vienna, also known as CVC and UC Berkeley. 

    According to Jacob Sherkow, a law professor at the University of Illinois, the ruling invalidates the current patents held by these biotech companies. Now they need to take the technology license fresh from Broad Institute. 

    The Broad Institute is a research group from Harvard University and the Massachusetts Institute of Technology. They cannot sue any biotech company until their drug is approved. The decisions on Monday cast a shadow over those companies that develop Crispr medicines with CVC licenses. However, CVC can appeal against the ruling. 

    An Intellia spokesperson said that the ruling did not affect their ongoing R&D programs plans, and Crisper Therapeutics also noted that the decision did not affect them, and their programs will continue.  

    Jennifer Doudna did not respond to the request for comment. Editas Medicine Inc., an exclusive agreement with Broad Institute, applauded the decision. Editas shares rose by 17% in late trading on Monday. 

    Intellia shares fell by 9.2% on the day in which it shared data on how to treat deadly liver diseases from a study using Crispr effectively. On the other side, Crisper Therapeutics fell by 1.4%.

    Biotech companies have started pursuing other gene-editing technologies like enzymes and other techniques such as base editing.


    RELATED ARTICLES

    Tesla’s Cheapest Cybertruck

    Tesla’s Cheapest Cybertruck Will Cost $60,990 in 2025

    Bloomberg News reports that after two years of delay and production glitches, Tesla Inc. has...
    JPMorgan’s S&P 500

    JPMorgan’s S&P 500 2024 Outlook Grimmest on Wall Street

    Bloomberg News reports that as the strategists on Wall Street are calling for an all-time...
    Fed Will Cut Interest Rates

    Fed Will Cut Interest Rates as Soon, Predicts Bill Ackman

    Bloomberg News reports that Bill Ackman, the billionaire investor, bets that the Federal Reserve will...
    AI Startup

    AI Startup of Google Raises $24 Million for Biotech Work

    Bloomberg News reports that the European biotech startup Cradle has raised as much as $24...
    Quantum Computing Lab

    Quantum Computing Lab Shut by Alibaba in Sign of Broader Cutback

    Bloomberg News reports that Alibaba Group Holding Ltd. has shuttered its quantum computing lab for...
    Water Damage Repairs

    Don’t DIY Water Damage Repairs to Your Business

    If your workplace ever suffers from water damage, you might be tempted to start fixing...
    MBA Programme

    Dual Degree MBA Programme: A Unique Educational Opportunity

    In today's world, professional success requires more than traditional management skills. It calls for a...
    women ipl

    Women IPL Sensation Shreyanka Patil: From Fan to Champion

    In a cricketing universe usually ruled by dudes, Shreyanka Patil, the rookie wonder for Royal...
    Monetize Magnet

    Monetize Magnet Review – The Best Crypto and Forex CPA Network

    In today's world, cryptocurrency has reached new heights, expanding continuously and providing online earning opportunities...
    celsius drink

    Celsius Drink – What Is It and How Safe Is It?

    These days, you must come across your social media feeds with an advertisement for a...
    low porosity hair

    Low Porosity Hair Problem? Slay Locks with Moisture Miracle

    Have you ever experienced your hair being stubbornly resistant to moisture? That's low porosity hair...